U.S. markets closed

Arvinas, Inc. (ARVN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
64.69+1.69 (+2.68%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close63.00
Open63.47
Bid50.00 x 1000
Ask75.00 x 800
Day's Range61.99 - 65.32
52 Week Range19.68 - 92.77
Volume298,198
Avg. Volume448,691
Market Cap3.162B
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is ARVN Stock A Buy or Sell?
    Insider Monkey

    Is ARVN Stock A Buy or Sell?

    Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

  • Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
    Zacks

    Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

    Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.92% and -70.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Arvinas: Q4 Earnings Insights

    Shares of Arvinas (NASDAQ:ARVN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 76.79% year over year to ($0.99), which missed the estimate of ($0.78). Revenue of $2,218,000 decreased by 54.67% year over year, which missed the estimate of $6,910,000. Outlook Earnings guidance hasn't been issued by the company for now. View more earnings on ARVN Arvinas hasn't issued any revenue guidance for the time being. Recent Stock Performance 52-week high: $92.77 52-week low: $19.68 Price action over last quarter: Up 256.56% Company Profile Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. See more from BenzingaClick here for options trades from BenzingaRecap: Biohaven Pharmaceutical Q4 EarningsSuperior Group: Q4 Earnings Insights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.